Inter Valley Health Plan Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pomona, CA. To find more information about Inter Valley Health Plan Inc., please visit www.ivhp.com
Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine and The Children`s Hospital at Penn State Health Milton S. Hershey Medical Center are committed to enhancing the quality of life through improved health, the professional preparation of those who will serve the health needs of others, and the discovery of knowledge that will benefit all.
Sawtooth Labs is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 100 years, VNA Health Group`s visiting nurses of NJ have made a difference in people`s lives Compassionate, caring, patient-centered, home- and community-based care delivered to you by people who take the time to know you, not just your medical history. We bring advanced care to where you`re most comfortable and can heal the fastest— in your home or wherever you reside. Each year, as the largest, non-profit visiting nurse association in New Jersey, our inter-disciplinary team provide services to more than 120,000 of your neighbors and friends, perhaps even you or someone you love. We are proud to know that we help make our community a healthier place. Whether it`s providing care for children with special needs or in-home care for seniors, we can help.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.